Advarra’s announcement of a new risk‑based AI governance framework features Raghu Punnamraju, CTO of Velocity Clinical Research, underscoring Velocity’s role in advancing responsible AI in clinical trials.
Velocity is a founding member of the Council for Responsible Use of AI in Clinical Trials, a cross‑industry group convened by Advarra that brings together leaders from biopharma, AI‑native drug discovery, and site‑level trial operations to advance responsible, patient‑centered AI adoption in clinical research.
The Council’s first deliverable introduces a practical governance framework that evaluates AI applications based on two key dimensions:
• Level of autonomy (how independently an AI system acts)
• Degree of patient impact (how directly it influences participant safety, access, monitoring, and evidence generation)
By aligning governance rigor with real‑world risk, this model moves beyond one‑size‑fits‑all controls and supports innovation while maintaining scientific integrity, transparency, and trust.
As Raghu notes, the real opportunity for AI in clinical trials lies in tools that reduce operational friction, support better decisions, and make the work of investigators and study teams more manageable—and this framework helps chart that path forward.
Learn more and access the full framework: https://www.advarra.com/industry-report/operationalizing-responsible-artificial-intelligence-ai-in-clinical-research/
